

priorities or by their access to non-market sources of capital, do not engage in unreasonable below-market pricing practices which could disrupt trade or harm privately-owned shipping companies.

The controlled carrier list is not a comprehensive list of foreign-owned or controlled ships or ship owners; rather, it is only a list of ocean common carriers that are controlled by governments. See 46 U.S.C. 40102(9). Thus, tramp operators and other non-common carriers are not included, nor are non-vessel-operating common carriers, regardless of their ownership or control.

The controlled carrier list was last updated on July 1, 2024. See 89 FR 54460. This notice revises the list to add Anji Shipping Co., Ltd. as a controlled carrier of the government of the People's Republic of China. Accordingly, Anji Shipping Co., Ltd. is now subject to the requirements of 46 U.S.C. 40701–40706, and to the Commission's regulations relating to controlled carriers. It is also subject to the provisions of 46 U.S.C. 40502(f).

There are no changes to report with respect to the remaining controlled carriers on the list.

It is requested that any other information regarding possible omissions or inaccuracies in this list be provided to the Commission's Office of the General Counsel at [generalcounsel@fmc.gov](mailto:generalcounsel@fmc.gov). See 46 CFR 501.12.

The amended list of currently classified controlled carriers and their corresponding Commission-issued Registered Persons Index numbers is set forth below:

(1) COSCO SHIPPING Lines Co., Ltd. (RPI No. 015614)—People's Republic of China;

(2) Orient Overseas Container Line Limited (RPI No. 011398)—People's Republic of China;

(3) OOCL (Europe) Limited (RPI No. 024786)—People's Republic of China;

(4) Hede (HONGKONG) International Shipping Limited (RPI No. 033332)—People's Republic of China;

(5) HMM (RPI No. 001452)—Republic of Korea;

(6) Anji Shipping Co., Ltd. (RPI No. 033604)—People's Republic of China.

By the Commission.

**David Eng,**  
Secretary.

[FR Doc. 2024–15752 Filed 7–17–24; 8:45 am]

**BILLING CODE 6730-02-P**

## FEDERAL RETIREMENT THRIFT INVESTMENT BOARD

### Notice of Board Meeting

**DATES:** July 23, 2024 at 10:00 a.m. EDT.

**ADDRESSES:** Telephonic. Dial-in (listen only) information: Number: 1–202–599–1426, Code: 140 856 172 #; or via web: [https://teams.microsoft.com/l/meetup-join/19%3ameeting\\_NzEzOTlkZmQtODI0ZS00ZTBhLWJhNmYtMGI1Y2M0OTUzYWYx%40thread.v2/0?context=%7b%22Tid%22%3a%223f6323b7-e3fd-4f35-b43d-1a7afae5910d%22%2c%22Oid%22%3a%221a441fb8-5318-4ad0-995b-f28a737f4128%22%7d](https://teams.microsoft.com/l/meetup-join/19%3ameeting_NzEzOTlkZmQtODI0ZS00ZTBhLWJhNmYtMGI1Y2M0OTUzYWYx%40thread.v2/0?context=%7b%22Tid%22%3a%223f6323b7-e3fd-4f35-b43d-1a7afae5910d%22%2c%22Oid%22%3a%221a441fb8-5318-4ad0-995b-f28a737f4128%22%7d).

**FOR FURTHER INFORMATION CONTACT:** Kimberly Weaver, Director, Office of External Affairs, (202) 942–1640.

**SUPPLEMENTARY INFORMATION:** Board Meeting Agenda.

### Open Session

1. Approval of the June 25, 2024, Board Meeting Minutes
2. Monthly Reports
  - (a) Participant Report
  - (b) Legislative Report
3. Quarterly Reports
  - (c) Investment Review
  - (d) Budget Review
  - (e) Audit Status
4. Internal Audit Update
5. OI Annual Presentation

### Closed Session

6. Information covered under 5 U.S.C. 552b (c)(9)(B) and (c)(10).

*Authority:* 5 U.S.C. 552b (e)(1).

Dated: July 12, 2024.

**Dharmesh Vashee,**

*General Counsel, Federal Retirement Thrift Investment Board.*

[FR Doc. 2024–15754 Filed 7–17–24; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### National Center for Health Statistics, Meeting of the ICD–10 Coordination and Maintenance Committee

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of meeting.

**SUMMARY:** The Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS),

Classifications and Public Health Data Standards Staff, announces the following meeting of the ICD–10 Coordination and Maintenance (C&M) Committee. This meeting is open to the public, limited only by the number of audio lines available. Online registration is required.

**DATES:** The meeting will be held on September 10, 2024, from 9 a.m. to 5 p.m., EDT, and September 11, 2024, from 9 a.m. to 5 p.m., EDT.

**ADDRESSES:** This is a virtual meeting. Register in advance at [https://cms.zoomgov.com/webinar/register/WN\\_8hiZrGNcQYCFuH9P7LCloQ](https://cms.zoomgov.com/webinar/register/WN_8hiZrGNcQYCFuH9P7LCloQ). The Meeting ID is 160 744 0104; the Passcode is 621302. After registering, you will receive a confirmation email containing information about joining the meeting. Further information will be provided on each of the respective web pages when it becomes available. For CDC, NCHS: <https://www.cdc.gov/nchs/icd/icd-10-maintenance/meetings.html>. For the Centers for Medicare & Medicaid Services, Department of Health and Human Services: <https://www.cms.gov/medicare/coding-billing/icd-10-codes/icd-10-coordination-maintenance-committee-materials>.

#### FOR FURTHER INFORMATION CONTACT:

Traci Ramirez, Medical Classification Specialist, National Center for Health Statistics, Centers for Disease Control and Prevention, 3311 Toledo Road, Hyattsville, Maryland 20782–2064. Telephone: (301) 458–4454; Email: [TRamirez@cdc.gov](mailto:TRamirez@cdc.gov).

#### SUPPLEMENTARY INFORMATION:

*Purpose:* The ICD–10 Coordination and Maintenance (C&M) Committee is a public forum for the presentation of proposed modifications to the International Classification of Diseases, Tenth Revision, Clinical Modification (CM) and ICD–10 Procedure Coding System (PCS).

*Matters to be Considered:* The tentative agenda will include discussions on the ICD–10–CM and ICD–10–PCS topics listed below. Agenda items are subject to change as priorities dictate. Please refer to the posted agenda for updates one month prior to the meeting.

ICD–10–PCS Topics:

1. Transcatheter Atrial Shunt Bypass \*
2. Administration of Roctavian
3. Temporary Transvenous Diaphragm Activation \*\*\*
4. Administration of emapalumab-lzsg \*\*
5. Insertion of Endovascular Anchors
6. External Fixation with Automated Strut Adjustment \*
7. Extracorporeal Interstitial Fluid Removal \*\*

## 8. Administration of tarlatamab-dlle \*\*

## 9. Intraoperative Donor Organ

Protection in Renal Transplantation

## 10. Section X Updates

## 11. Addenda and Key Updates \*

\* Request is for an April 1, 2025, implementation date.

\*\* Request is for an April 1, 2025, implementation date, and the requestor intends to submit a new technology add-on payment (NTAP) application for FY 2026 consideration.

\*\*\* Requestor intends to submit an NTAP application for FY 2026 consideration.

Presentations for procedure code requests are conducted by both the requestor and the Centers for Medicare & Medicaid Services (CMS) during the C&M Committee meeting. Discussion from the requestor generally focuses on the clinical issues for the procedure or technology, followed by the proposed coding options from a CMS analyst. Topics presented may also include requests for new procedure codes that relate to a new technology add-on payment (NTAP) policy request.

CMS has modified the approach for presenting the NTAP-related ICD-10-PCS procedure code requests that involve the administration of a therapeutic agent. For the September 10-11, 2024, ICD-10 C&M Committee meeting, consistent with the requirements of section 1886(d)(5)(K)(iii) of the Social Security Act, applicants submitted requests to create a unique procedure code to describe the administration of a therapeutic agent, such as the option to create a new code in Section X within the ICD-10-PCS procedure code classification. CMS will initially display only those meeting materials associated with the NTAP-related ICD-10-PCS procedure code requests that involve the administration of a therapeutic agent on the CMS website in August 2024 at: <https://www.cms.gov/medicare/coding-billing/icd-10-codes/icd-10-coordination-maintenance-committee-materials>.

The NTAP-related ICD-10-PCS procedure code requests that involve the administration of a therapeutic agent are:

1. Administration of emapalumab-lzsg \*\*
2. Administration of tarlatamab-dlle \*\*

\*\* Request is for an April 1, 2025, implementation date, and the requestor intends to submit an NTAP application for FY 2026 consideration..

These topics will not be presented during the September 10-11, 2024, meeting. CMS will solicit public

comments regarding any clinical questions or coding options included for these procedure code topics in advance of the meeting continuing through the end of the respective public comment periods. Members of the public should send any questions or comments to the CMS mailbox at:

*ICDProcedureCodeRequest@cms.hhs.gov*.

CMS intends to post a question-and-answer document in advance of the meeting to address any clinical or coding questions that members of the public may have submitted. Following the conclusion of the meeting, CMS will post an updated question-and-answer document to address any additional clinical or coding questions that members of the public may have submitted during the meeting that CMS was not able to address or that were submitted after the meeting.

The NTAP-related ICD-10-PCS procedure code requests that do not involve the administration of a therapeutic agent and all non-NTAP-related procedure code requests will continue to be presented during the virtual meeting on September 10, 2024, consistent with the standard meeting process.

CMS will make all meeting materials and related documents available at: <https://www.cms.gov/medicare/coding-billing/icd-10-codes/icd-10-coordination-maintenance-committee-materials>. Any inquiries related to the procedure code topics scheduled for the September 10-11, 2024, ICD-10 C&M Committee meeting that are under consideration for April 1, 2025, or October 1, 2025, implementation should be sent to the CMS mailbox at: *ICDProcedureCodeRequest@cms.hhs.gov*.

## ICD-10-CM Topics:

1. Abnormal Rheumatoid Factor and Anti-citrullinated Protein Antibody Without a Diagnosis of Rheumatoid Arthritis
2. Demodex Blepharitis
3. Encounter for Prophylactic Removal of Fallopian Tube(s) for Persons Without Known Genetic/Familial Risk Factors
4. Genetic Neurodevelopmental Disorders
5. Hypothalamic Obesity
6. Kabuki Syndrome
7. Topical Steroid Withdrawal
8. Usher Syndrome
9. Addenda

The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been

delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2024-15795 Filed 7-17-24; 8:45 am]

**BILLING CODE 4163-18-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Centers for Disease Control and Prevention****Safety and Occupational Health Study Section; Notice of Charter Renewal**

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of charter renewal.

**SUMMARY:** The Centers for Disease Control and Prevention (CDC), within the Department of Health and Human Services (HHS), announces the renewal of the charter of the Safety and Occupational Health Study Section (SOHSS).

**FOR FURTHER INFORMATION CONTACT:** Joanne Fairbanks, Designated Federal Officer, Safety and Occupational Health Study Section, Centers for Disease Control and Prevention, Department of Health and Human Services, 1095 Willowdale Road, Morgantown, West Virginia 26505. Telephone: (304) 285-6143; Email: *JFairbanks@cdc.gov*.

**SUPPLEMENTARY INFORMATION:** CDC is providing notice under 5 U.S.C. 1001 through 1014 of the renewal of the charter of the Safety and Occupational Health Study Section, Centers for Disease Control and Prevention, Department of Health and Human Services. This charter has been renewed for a two-year period through June 30, 2026.

The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and